We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LICN:NASDAQLichen International Limited Analysis

Data as of 2026-04-15 - not real-time

$5.11

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

LICN trades well above its short‑term moving averages, with the current price sitting above the 20‑day, 50‑day and 200‑day SMAs, suggesting residual bullish momentum. However, the MACD histogram is negative and the signal line is bearish, indicating a potential weakening of that momentum. The RSI sits in the upper‑mid 50s, far from overbought levels, so there is still room for price movement. Volatility is extreme, exceeding 200% over the past month, and the beta is above 1.3, pointing to heightened sensitivity to market swings. The company’s fundamentals are weak: earnings per share are deeply negative, operating margins are in the negative 30% range, and operating cash flow is also negative, while free cash flow is marginal. The DCF‑derived fair value is roughly $1.80, far below the current $5.10 price, indicating that the market may be overpaying relative to intrinsic estimates. Conversely, the price‑to‑book ratio of 0.06 is exceptionally low, reflecting a sizable discount to book value. A recent “Extreme Greed” sentiment reading underscores speculative enthusiasm despite the adverse financial picture. Volume trends are decreasing, adding to liquidity concerns, and the stock has suffered a historic drawdown of more than 50%.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Bearish MACD signal
  • Extreme price volatility
  • Price far above DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Low price‑to‑book offering potential value
  • Uncertain turnaround of operating margins
  • Persistently negative earnings

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained negative cash flow
  • High historical drawdown
  • Elevated beta and sector exposure

Key Metrics & Analysis

Financial Health

Revenue Growth-21.20%
Profit Margin-43.20%
ROE-23.98%
ROA-10.28%
Debt/Equity0.56
P/B Ratio0.1
Op. Cash Flow$-11113000
Free Cash Flow$540.2K
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI59.2
Support$2.87
Resistance$7.00
MA 20$4.42
MA 50$3.60
MA 200$3.83
MACDBearish
VolumeDecreasing
Fear & Greed Index88.64

Valuation

Fair Value$1.81
GradeOvervalued
TypeValue

Risk Assessment

Beta1.39
Volatility201.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.